Facilitation of resuscitation from cardiac arrest by erythropoietin
AssigneeRosalind Franklin University of Medicine and Science
InventorRaúl J. Gazmuri
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the use of erythropoietin (EPO) to facilitate resuscitation from cardiac arrest. For a mammalian subject suffering from cardiac arrest, concurrent administration of EPO with resuscitation after the onset of ventricular fibrillation facilitates the resuscitation. Administration of EPO serves to attenuate myocardial abnormalities caused by cardiac arrest and the resuscitation efforts and favor improved resuscitation outcomes.
Claims20
A method for preserving left ventricular myocardial distensibility during cardiopulmonary resuscitation whereby the hemodynamic efficacy of chest compression improves in a mammalian subject suffering from cardiac arrest comprising administration of an effective amount of erythropoietin (EPO), wherein the EPO is wildtype or recombinant wildtype EPO, to the subject concurrent with cardiac resuscitation to increase the ratio of coronary perfusion pressure (CPP) to depth of chest compression.
A method for preserving left ventricular myocardial distensibility during cardiopulmonary resuscitation whereby the hemodynamic efficacy of chest compression improves in a mammalian subject suffering from cardiac arrest comprising administration of an effective amount of erythropoietin (EPO), wherein the EPO is wildtype or recombinant wildtype EPO, to the subject concurrent with cardiac resuscitation at a time between the onset of cardiac arrest and post resuscitation to increase the ratio of coronary perfusion pressure (CPP) to depth of chest compression.
Dependencies are inferred from the claim text.